Hope for Alzheimer's: HMTM drug slows brain deterioration
The new HMTM drug can slow cognitive decline in Alzheimer's disease. Clinical trial results and the prospects for the drug becoming available in Uzbekistan.
The new HMTM drug can slow cognitive decline in Alzheimer's disease. Clinical trial results and the prospects for the drug becoming available in Uzbekistan.
In a world where dementia cases are growing every year, scientists have taken a major step forward. The new drug Hydromethylthionine mesylate (HMTM) has demonstrated the ability to slow cognitive decline in patients with Alzheimer's disease.
Alzheimer's disease is linked to the accumulation of abnormal tau protein in the brain, which destroys neural connections. HMTM prevents the formation of these proteins and stabilises brain activity. In practice, this means preserving memory, orientation, speech and the ability to live independently.
Patients taking HMTM showed disease progression 85% slower compared to the control group. This has given hope to millions of families whose loved ones suffer from memory loss and cognitive impairment.
The drug is currently undergoing registration in the United Kingdom and Canada. It is expected to become available in other countries by 2026. It is not yet registered in Uzbekistan, but doctors are already tracking the clinical results and preparing for its arrival.
At Horev Medical clinic, you can consult a neurologist, undergo an ultrasound of the neck and brain vessels, take laboratory tests and complete cognitive screening. Early detection of memory disorders is the key to extending an active and clear-minded life.
Book a visit — we will pick a convenient time.